Health

CMS decision on Aduhelm could shock state Medicaid programs


CMS decision on Aduhelm could shock state Medicaid programs

Shortly after the controversial Biogen drug for Alzheimer’s was approved in the U.S. last year, a pair of state Medicaid directors tried to ring alarm bells.

In a terse letter, they implored the Biden administration to ensure Medicare covers the medicine, despite limited effectiveness and a $56,000 price tag. Their reasoning was simple: If Medicare reacted to the highly questionable approval by withholding or restricting coverage, Medicaid would be left holding the proverbial bag, because by law it must cover drugs endorsed by the Food and Drug Administration.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED




Source link

Check Also
Close
Back to top button